Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)Xiuning Le, Jyoti D Patel, Elaine Shum, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS StudyMatthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.Targeted Oncology|November 3, 2025
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyRachel E Sanborn, Caicun Zhou, Ke-Jing Tang, et al.Nucleic Acids Research|November 17, 2025
African Natural Products Database (ANPDB): A resource for exploring the therapeutic potential of natural compounds from AfricaJude Y Betow, Ammar Qaseem, Boris D Bekono, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyKeunchil Park, Eric B Haura, Natasha B Leighl, et al.JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.Nature Medicine|February 27, 2025
Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastasesSomnath Tagore, Lindsay Caprio, Amit Dipak Amin, et al.Cancer Discovery|April 16, 2023
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant MalignanciesPrabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, et al.Pageof 8